Skip to main content

Table 1 Characteristics of prescriptions included in analyses as compared to all prescriptions

From: Prescribing Alzheimer’s Disease treatments by provider type and geographic region: a comparison among physicians, nurse practitioners, and physician assistants

Alzheimer’s Disease Cohort
  Included in Analysis All Unique Prescriptions
Patient Demographics
 Age: Mean (SD) 75.22 (13.91) 78.86 (12.43)
 Gender (% Female) 57.64% 58.12%
Prescriptions (n (%))
 Donepezil 57,749 (56%) 375,576 (50%)
 Galantamine 1,463 (1%) 14,210 (2%)
 Rivastigmine 7,664 (8%) 61,521 (8%)
 Memantine 34,555 (34%) 276,092 (37%)
 Donepezil and Memantine 1,306 (1%) 1,935 (0.3%)
 Total 103,067 744,180
 Days Supply: Mean (SD) 44.71 (30.00) 42.37 (31.10)
Osteoporosis Cohort
  Included in Analysis All Unique Prescriptions
Patient Demographics
 Age: Mean (SD) 63.59 (10.32) 64.54 (10.70)
 Gender (% Female) 92.66% 92.82%
Prescriptions (n (%))
 Abaloparatide 229 (0.2%) 2832 (0.4%)
 Alendronate 80,539 (61%) 395,836 (56%)
 Alendronate/Cholecalciferol 120 (0.1%) 964 (0.1%)
 Denosumab 3,280 (2%) 36,970 (5%)
 Ibandronate 18,585 (14%) 90,178 (13%)
 Raloxifene 16,704 (13%) 102,461 (14.5%)
 Risedronate 10,766 (8%) 57,811 (8%)
 Teriparatide 1,362 (1%) 17,624 (2%)
 Zoledronic Acid 185 (0.1%) 1,734 (0.25%)
 Romosozumab-aqqg 3 35
    Total 131,773 706,445
 Days Supply: Mean (SD) 60.65 (33.67) 62.72 (37.21)
  1. Abbreviations: SD Standard Deviation